Centauri develops advanced therapies with mesenchymal stem cells (MSCs) in the veterinary field for the treatment of osteoarthritis, atopy, and immune-based diseases in pets, entertainment animals and competition animals. MSCs are adult cells with the capacity to differentiate into different tissues and with an anti-inflammatory effect, causing no rejection or side effects.
These therapies are provided by means of autologous services and allogenic products.
Autologous services are those therapies in which the donor and the recipient are the same animal. Therapies with autologous cells are considered by the European Medicines Agency (EMA) to be a service provision.
Regarding the products, therapies based on allogenic cells, in which a donor is used to treat thousands of other animals, are considered by the EMA to be a medicinal product.
Nowadays, Centauri commercializes autologous therapies for the treatment of osteoarthritis, IBD and skin atopy. The company is already developing the first allogenic cell therapy drug for the treatment of osteoarthritis in horses.